0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
Volume 13, Issue 3 (2021)
3 2021, 13(3): 199-202 |
Back to browse issues page
History
Received: 2021/08/16 | Accepted: 2021/08/25 | Published: 2021/11/11
Received: 2021/08/16 | Accepted: 2021/08/25 | Published: 2021/11/11
How to cite this article
Awad W, Kadhim H, Hassan D, Al-Yassiry K. Risk of Mortality due to Sudden Hyperglycemia in COVID-19 Patients. 3 2021; 13 (3) :199-202
URL: http://ijwph.daneshafarand.org/article-3-85416-en.html
URL: http://ijwph.daneshafarand.org/article-3-85416-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Biochemistry, College of Medicine, University of Kerbala, Kerbala, Iraq
2- Department of Physiology and Medical Physics, College of Medicine, University of Al-Ameed, Kerbala, Iraq
3- Department of Biochemistry, Health and Medical Technical College, Women University of Al-Zahraa, Kerbala, Iraq
4- Department of Pharmacology, College of Medicine, University of Kerbala, Kerbala, Iraq
2- Department of Physiology and Medical Physics, College of Medicine, University of Al-Ameed, Kerbala, Iraq
3- Department of Biochemistry, Health and Medical Technical College, Women University of Al-Zahraa, Kerbala, Iraq
4- Department of Pharmacology, College of Medicine, University of Kerbala, Kerbala, Iraq
Abstract (3528 Views)
Aims: One of the most dangerous complications of COVID-19 is sudden hyperglycemia that may carry a high incidence of the death rate. This study aimed to evaluate the relationship between death rate and hyperglycemia caused by COVID-19 infection in non-diabetic patients.
Materials & Methods: In this study, 296 patients were selected randomly, 57 patients complaining of sudden hyperglycemia (>400 mg/dl) one week after the high fever subsided; the others did not show such complain. Statistical analysis was done to evaluate the relative risk of hyperglycemia upon the incidence of mortality rate between two groups.
Findings: The X2 value was 20.5959 for all, and the p-value was not significant except for COVID-19 with hyperglycemia that showed a highly significant mortality rate (X2=15.9, p<0.001).
Conclusion: Hyperglycemia should be monitored even after regression of COVID-19 symptoms, and insulin therapy must be considered to minimize the risk of death.
Materials & Methods: In this study, 296 patients were selected randomly, 57 patients complaining of sudden hyperglycemia (>400 mg/dl) one week after the high fever subsided; the others did not show such complain. Statistical analysis was done to evaluate the relative risk of hyperglycemia upon the incidence of mortality rate between two groups.
Findings: The X2 value was 20.5959 for all, and the p-value was not significant except for COVID-19 with hyperglycemia that showed a highly significant mortality rate (X2=15.9, p<0.001).
Conclusion: Hyperglycemia should be monitored even after regression of COVID-19 symptoms, and insulin therapy must be considered to minimize the risk of death.
Keywords: